How are SLS strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SLS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 150.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$180.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a SLS strangle?

The breakeven for the SLS strangle priced on this page is roughly $4.70 and $9.30 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLS market-implied 1-standard-deviation expected move is approximately 43.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current SLS implied volatility affect this strangle?

SLS ATM IV is at 150.40% with IV rank near 33.98%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

SLS Strangle Strategy

SLS (SELLAS Life Sciences Group, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

SLS (SELLAS Life Sciences Group, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $930.1M, a beta of 2.24 versus the broader market, a 52-week range of 1.39-6.72, average daily share volume of 6.3M, a public-listing history dating back to 2008, approximately 15 full-time employees. These structural characteristics shape how SLS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.24 indicates SLS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on SLS?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current SLS snapshot

As of May 15, 2026, spot at $7.06, ATM IV 150.40%, IV rank 33.98%, expected move 43.12%. The strangle on SLS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.

Why this strangle structure on SLS specifically: SLS IV at 150.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 43.12% (roughly $3.04 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SLS expiries trade a higher absolute premium for lower per-day decay. Position sizing on SLS should anchor to the underlying notional of $7.06 per share and to the trader's directional view on SLS stock.

SLS strangle setup

The SLS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SLS near $7.06, the first option leg uses a $7.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SLS chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SLS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$7.50	$1.05
Buy 1	Put	$6.50	$0.75

SLS strangle risk and reward

Net Premium / Debit: -$180.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$180.00
Breakeven(s): $4.70, $9.30
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

SLS strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on SLS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$469.00
$1.57	-77.8%	+$313.01
$3.13	-55.7%	+$157.02
$4.69	-33.6%	+$1.03
$6.25	-11.5%	-$154.96
$7.81	+10.6%	-$149.05
$9.37	+32.7%	+$6.94
$10.93	+54.8%	+$162.93
$12.49	+76.9%	+$318.92
$14.05	+99.0%	+$474.91

When traders use strangle on SLS

Strangles on SLS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SLS chain.

SLS thesis for this strangle

The market-implied 1-standard-deviation range for SLS extends from approximately $4.02 on the downside to $10.10 on the upside. A SLS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current SLS IV rank near 33.98% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on SLS should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SLS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SLS-specific events.

SLS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SLS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SLS alongside the broader basket even when SLS-specific fundamentals are unchanged. Always rebuild the position from current SLS chain quotes before placing a trade.

Frequently asked questions

What is a strangle on SLS?: A strangle on SLS is the strangle strategy applied to SLS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With SLS stock trading near $7.06, the strikes shown on this page are snapped to the nearest listed SLS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SLS strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the SLS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 150.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$180.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SLS strangle?: The breakeven for the SLS strangle priced on this page is roughly $4.70 and $9.30 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLS market-implied 1-standard-deviation expected move is approximately 43.12%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on SLS?: Strangles on SLS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the SLS chain.
How does current SLS implied volatility affect this strangle?: SLS ATM IV is at 150.40% with IV rank near 33.98%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.